BrainStorm Cell Therapeutics Names Dr. Revital Geffen-Aricha as VP of R&D

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) announced today that it has appointed Dr. Revital Geffen-Aricha, M.Sc., Ph.D., as Vice President of Research and Development.  Dr. Geffen-Aricha will be based in Israel and report to Chaim Lebovits, President and Chief Executive Officer. She will be responsible for all research and development activities for BrainStorm."We are excited to have someone of Revital's experience and capabilities join the Brainstorm team," stated Chaim Lebovits. "She has already made significant contributions since joining the company in March 2015. We look forward to her leadership as we advance NurOwn® through the clinic in ALS and continue our efforts to explore the full potential of NurOwn® to treat patients suffering from additional CNS disorders.""There is a very significant unmet need for innovation in the treatment of CNS disorders and Brainstorm is developing cell therapies that have the potential to transform how these diseases are treated," said Dr. Geffen-Aricha. "I look forward to leading the team in advancing the promising NurOwn® development programs." Dr. Geffen-Aricha joined BrainStorm from the Weizmann Institute of Science, where she served as See full press release